About Us
Our Story
Science
Pipeline
Type 1 Diabetes
Heart Failure
Chronic Kidney Disease
SGLT1/2 Inhibition
Mechanism of Action
News and Investors
Press Releases
Industry Dynamics
Contact

国内首个SGLT1/2获中国NMPA临床许可

2019-02-12 00:00:00
Return

  2019年2月,YG1699获得中国NMPA临床试验许可。

Previous:YG1699已完成单剂量爬坡,40位受试者已完成给药。
Next:国内首个SGLT1/2获美国FDA临床许可

More news

  • Lexicon Preparing to Resubmit Sotag...

  • Positive Results of a YG1699 Phase ...

  • Does SGLT1 Inhibition Add to the Be...

© 2022 YOUNGENE ALL RIGHTS RESERVED    PHONE:021-50772330    E-MAIL:jacky.li@youngene.com   Technical support:jjcloudservice